Acquired
Novo Nordisk (Ozempic)
David Rosenthal
And Novo gets swept up in it. They're like, oh no, Eli Lilly, they're going to come back into the research game. They're going to innovate in product. We had the chance to work with Genentech. Genentech had actually approached them about being a partner in Europe. Novo had turned them down because they didn't think the science was ready yet and they were wrong.
0
💬
0
Comments
Log in to comment.
There are no comments yet.